Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $161,007.20 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 25,040 shares of Clene stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $6.43, for a total transaction of $161,007.20. Following the completion of the sale, the insider owned 362,729 shares of the company’s stock, valued at $2,332,347.47. This trade represents a 6.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The stock was sold at an average price of $6.40, for a total transaction of $49,587.20.
• On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The stock was sold at an average price of $6.48, for a total transaction of $41,303.52.
• On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The stock was sold at an average price of $4.81, for a total transaction of $119,889.25.
• On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The stock was sold at an average price of $4.97, for a total transaction of $21,261.66.
• On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The stock was sold at an average price of $4.10, for a total transaction of $22,791.90.
• On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total transaction of $15,352.00.
• On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total transaction of $23,483.18.
• On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The stock was sold at an average price of $4.32, for a total transaction of $66,026.88.
• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total transaction of $21,026.12.

Clene Price Performance

CLNN stock opened at $6.31 on Monday. Clene Inc. has a 12 month low of $2.28 and a 12 month high of $13.50. The firm has a market cap of $74.33 million, a P/E ratio of -2.43 and a beta of 0.62. The company’s 50-day moving average price is $5.36 and its two-hundred day moving average price is $6.66.

Clene (NASDAQ:CLNN) last released its earnings results on Thursday, March 12th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.03 million. Equities analysts predict that Clene Inc. will post -5.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on CLNN. D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of Clene in a report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 target price on shares of Clene in a report on Friday, March 13th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clene presently has an average rating of “Moderate Buy” and an average target price of $33.00.

Institutional Investors Weigh In On Clene

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp bought a new stake in shares of Clene during the 3rd quarter valued at approximately $29,000. Jane Street Group LLC bought a new stake in shares of Clene during the 2nd quarter valued at approximately $47,000. State Street Corp grew its holdings in shares of Clene by 138.4% during the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after purchasing an additional 17,300 shares during the last quarter. PEAK6 LLC bought a new stake in shares of Clene during the 4th quarter valued at approximately $294,000. Finally, Lunt Capital Management Inc. grew its holdings in shares of Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after purchasing an additional 1,250 shares during the last quarter. 23.28% of the stock is owned by institutional investors.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).